Related Experiment Video
Updated: Jun 5, 2026
06:41
A New Technique for Quantitative Analysis of Hair Loss in Mice Using Grayscale Analysis
Published on: March 9, 2015
Topical immunotherapy in alopecia areata.
1Department of Dermatology and STD, Sri Devaraj Urs Medical College, Tamaka, Kolar - 563 101, India.
International Journal of Trichology
|December 29, 2010
Summary
Topical immunotherapy using diphencyprone (DPCP) or squaric acid dibutylester (SADBE) effectively treats severe alopecia areata (AA). These non-mutagenic agents offer comparable results, with DPCP showing high efficacy in patchy AA.
Area of Science:
- Dermatology
- Immunology
Background:
- Alopecia Areata (AA) is a common non-scarring hair loss condition affecting the anagenic hair follicle.
- Severe and refractory cases of AA often require specialized treatment modalities.
Purpose of the Study:
- To review the efficacy and safety of topical immunotherapy agents for severe Alopecia Areata.
- To compare the effectiveness of Dinitrochlorobenzene (DNCB), Squaric Acid Dibutylester (SADBE), and Diphencyprone (DPCP).
Main Methods:
- Review of documented treatment modalities for severe Alopecia Areata.
- Focus on contact immunotherapy agents: DNCB, SADBE, and DPCP.
- Analysis of efficacy, relapse rates, mutagenicity, and cost-effectiveness.
Main Results:
- Dinitrochlorobenzene (DNCB) is mutagenic and largely replaced by SADBE and DPCP.
- SADBE and DPCP are non-mutagenic with comparable efficacy and relapse rates.
- DPCP demonstrates variable response rates (60% in severe AA, 17% in alopecia totalis/universalis, 88-100% in patchy AA). SADBE is more expensive and requires special additives.
Conclusions:
- Topical immunotherapy with SADBE and DPCP is a well-documented treatment for severe Alopecia Areata.
- DPCP and SADBE are preferred over DNCB due to their non-mutagenic profiles.
- DPCP shows significant efficacy, particularly in patchy Alopecia Areata.
Related Concept Videos
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
01:30Skin Cancer
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
01:23Skin Diseases and Disorders
Skin is the first line of defense and encounters a variety of microbes. Some pathogenic strains are often the cause of a broad range of infections of the skin and other body systems. These conditions can affect people of all ages and may have different causes, including genetic factors, infections, autoimmune reactions, environmental factors, and lifestyle choices.
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...